SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
___________
FORM 8-K
CURRENT REPORT
Pursuant to Section 13
or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): May 15, 2001
INTEGRA LIFESCIENCES HOLDINGS CORPORATION |
(Exact name of registrant as specified in its charter) |
Delaware |
0-26224 |
51-0317849 |
(State or other jurisdiction | (Commission | (IRS Employer |
of incorporation) | File Number) | Identification No.) |
311-C Enterprise Drive | |
Plainsboro, New Jersey |
08536 |
(Address of principal executive offices) | (Zip Code) |
Registrant's telephone number, | ||
including area code: | (609) 275-0500 |
|
Not
Applicable |
(Former name or former address, if changed since last report) |
Item 5. Other Events
The Company's Annual Meeting of Stockholders was held on May 15, 2001 and in connection therewith, proxies were solicited by management pursuant to Regulation 14A under the Securities Exchange Act of 1934, as amended. An aggregate of 17,642,155 shares of the Company's common stock ("Common Stock"), 100,000 shares of Series B Preferred Stock (which are convertible into 2,617,801 shares of Common Stock), and 54,000 shares of Series C Preferred Stock (which are convertible into 600,000 shares of Common Stock) (collectively, "Shares") were outstanding and entitled to a vote at the meeting. At the meeting the following matters (not including ordinary procedural matters) were submitted to a vote of the holders of Shares, with the results indicated below:
1. Election of directors to serve until the 2002 Annual Meeting. The following persons, all of whom were serving as directors and were management's nominees for election, were elected. There was no solicitation in opposition to such nominees. The tabulation of votes was as follows:
Nominee
|
For
|
Withheld
|
Keith Bradley | 18,100,636 | 405,740 |
Richard E. Caruso | 18,100,636 | 405,740 |
Stuart M. Essig | 16,544,957 | 1,961,419 |
Neil Moszkowski | 18,101,136 | 405,240 |
George W. McKinney, III | 16,537,857 | 1,968,519 |
James M. Sullivan | 18,101,136 | 405,240 |
2. Approval of the Company's 2001 Equity Incentive Plan. The Company's 2001 Equity Incentive Plan was approved. The tabulation of votes was as follows:
For
|
Against
|
Abstentions
|
13,811,174 | 2,392,352 | 22,910 |
3. Ratification and approval of an amendment to the Companys Certificate of Designation, Rights and Preferences of Series B Convertible Preferred Stock, the purpose of which was to ensure that the rights and preferences of the Series B Convertible Preferred Stock would be substantially identical to the rights and preferences of the Series C Convertible Preferred Stock. This amendment was approved. The tabulation of votes was as follows:
For
|
Against
|
Abstentions
|
16,116,674 | 74,884 | 34,878 |
4. Approval of an amendment to the Companys Certificate of Designation, Rights and Preferences of Series B Convertible Preferred Stock, the purpose of which is to make certain changes to clarify the numbering of certain paragraphs and internal references contained therein. This amendment was approved. The tabulation of votes was as follows:
For
|
Against
|
Abstentions
|
16,135,626 | 57,625 | 33,185 |
5. Approval of an amendment to the Companys Certificate of Designation, Rights and Preferences of Series C Convertible Preferred Stock, the purpose of which is to make certain changes to clarify the numbering of certain paragraphs and internal references contained therein. This amendment was approved. The tabulation of votes was as follows:
For
|
Against
|
Abstentions
|
16,135,020 | 58,204 | 33,212 |
6. Ratification of independent auditors. The appointment of PricewaterhouseCoopers LLP as the Company's independent auditors for the current fiscal year was ratified. The tabulation of votes was as follows:
For
|
Against
|
Abstentions
|
18,477,510 | 22,744 | 6,122 |
ITEM 7. Financial Statements and Exhibits.
(c) Exhibits.
Exhibit
Number (Referenced to Item 601 of Regulation S-K) |
Description
of Exhibit
|
(3)(i).1 | Second Amendment to
Certificate of Rights, Designations and Preferences of Series B Convertible Preferred Stock |
(3)(i).2 | First Amendment to
Certificate of Rights, Designations and Preferences of Series C Convertible Preferred Stock |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
INTEGRA
LIFESCIENCES HOLDINGS CORPORATION |
|
Date: May 25, 2001 | By: /s/ Stuart M. Essig
|
Stuart
M. Essig, President and Chief Executive Officer |
|
INDEX OF EXHIBITS
Exhibit
No.
|
Description
of Exhibit
|
(3)(i).1 | Second Amendment to
Certificate of Rights, Designations and Preferences of Series B Convertible Preferred Stock |
(3)(i).2 | First Amendment to
Certificate of Rights, Designations and Preferences of Series C Convertible Preferred Stock |
Exhibit 3(i).1
INTEGRA LIFESCIENCES HOLDINGS CORPORATION
SECOND
AMENDMENT TO CERTIFICATE OF
DESIGNATION, RIGHTS AND PREFERENCES OF
SERIES B CONVERTIBLE PREFERRED STOCK
Section 242
INTEGRA LIFESCIENCES HOLDINGS CORPORATION ("Integra"), a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware, DOES HEREBY CERTIFY:
FIRST: That the Board of Directors of Integra, at a meeting held on March 6, 2001, adopted the following resolution proposing and declaring advisable certain amendments (the "Series B Amendment") to the Certificate of Designation, Rights and Preferences of Series B Convertible Preferred Stock of Integra as filed with the Office of the Secretary of State of the State of Delaware on March 12, 1999 and amended March 21, 2000:
RESOLVED, that this Board of Directors proposes and hereby deems advisable that the Certificate of Designation, Rights and Preferences of Series B Convertible Preferred Stock of Integra Lifesciences Holdings Corporation (the "Series B Certificate"), be amended as follows:
(1) Amend paragraph 4 thereof so that, as amended, said paragraph shall be and read in its entirety as follows:
(a) Upon any liquidation, dissolution or winding up of the Corporation, whether voluntary or involuntary, in which all or substantially all of the consideration, if any, received by the Corporation or its stockholders is in cash, the holders of the shares of Series B Convertible Preferred Stock shall be paid, before any distribution or payment is made upon any stock ranking on liquidation junior to the Series B Convertible Preferred Stock, an amount equal to the greater of (i) $100 per share (the "Redemption Payment") and (ii) the amount that the holders of the Series B Convertible Preferred Stock would receive if they were to convert each share of Series B Convertible Preferred Stock into shares of Common Stock immediately prior to such liquidation, dissolution or winding up (such amount payable with respect to one share of Series B Convertible Preferred Stock being sometimes referred to as the "Liquidation Payment" and with respect to all shares of Series B Convertible Preferred Stock being sometimes referred to as the "Liquidation Payments").
(b) Upon any liquidation, dissolution or winding up of the Corporation, whether voluntary or involuntary, in which all or substantially all of the consideration, if any, received by the Corporation or its stockholders is in securities, the Corporation shall have the option, at its election, of paying such Liquidation Payments to the holders of the shares of Series B Convertible Preferred Stock in cash or in a preferred security of the successor entity having terms substantially similar to the Series B Convertible Preferred Stock.
(c) If upon any liquidation, dissolution or winding up of the Corporation, whether voluntary or involuntary, the assets to be distributed among the holders of Series B Convertible Preferred Stock shall be insufficient to permit payment to the holders of Series B Convertible Preferred Stock of the Liquidation Payments, then the entire assets of the Corporation to be so distributed shall be distributed ratably among the holders of Series B Convertible Preferred Stock. Upon any liquidation, dissolution or winding up of the Corporation, after the holders of Series B Convertible Preferred Stock shall have been paid in full the Liquidation Payments respectively, to which they shall be entitled, the Series B Convertible Preferred Stock shall be automatically canceled and the remaining net assets of the Corporation may be distributed to the holders of stock ranking on liquidation junior to the Series B Convertible Preferred Stock.
(d) Written notice of such liquidation, dissolution or winding up, stating a payment date, the amount of the Liquidation Payments and the place where said Liquidation Payments shall be payable, shall be delivered in person, mailed by certified or registered mail, return receipt requested, or sent by telecopier or telex, not less than 10 days prior to the payment date stated therein, to the holders of record of Series B Convertible Preferred Stock, such notice to be addressed to each such holder at its address as shown by the records of the Corporation.
(f) The Series B Convertible Preferred Stock shall, with respect to distribution of assets and rights upon the liquidation, dissolution or winding up of the Corporation, rank on a parity with any class or series of capital stock of the Corporation hereafter created which expressly provides that it ranks on a parity with the Series B Convertible Preferred Stock with respect to distribution of assets and rights upon the liquidation, dissolution or winding up of the Corporation. The Series B Convertible Preferred Stock shall, with respect to distribution of assets and rights upon the liquidation, dissolution or winding up of the Corporation, rank senior to (i) the Corporation's Series A Convertible Preferred Stock, $.01 par value per share, and (ii) each class or series of capital stock of the Corporation hereafter created which does not expressly provide that it ranks on a parity with or senior to the Series B Convertible Preferred Stock with respect to distribution of assets and rights upon the liquidation, dissolution or winding up of the Corporation.";
(2) Amend paragraph 9(b) thereof by replacing the phrase "Series C Convertible Preferred Stock" that appears therein with the phrase "Series B Convertible Preferred Stock".
SECOND: That the stockholders of the Corporation, at an annual meeting of stockholders called and held upon notice properly given in accordance with Section 222 of the Delaware General Corporation Law, have adopted and approved the Series B Amendment in accordance with the provisions of Section 212 of the Delaware General Corporation Law.
IN WITNESS WHEREOF, said Integra LifeSciences Holdings Corporation has caused this Certificate of Amendment of Certificates of Designation, Rights and Preferences of Series B Preferred Stock to be executed by a duly authorized officer of the Corporation this 15th day of May, 2001.
INTEGRA LIFESCIENCES HOLDINGS CORPORATION | ||
By: | Stuart M. Essig
|
|
Stuart M. Essig, President | ||
Exhibit 3(i).2
INTEGRA LIFESCIENCES HOLDINGS CORPORATION
FIRST
AMENDMENT TO CERTIFICATE OF
DESIGNATION, RIGHTS AND PREFERENCES OF
SERIES C CONVERTIBLE PREFERRED STOCK
Section 242
INTEGRA LIFESCIENCES HOLDINGS CORPORATION ("Integra"), a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware, DOES HEREBY CERTIFY:
FIRST: That the Board of Directors of Integra, at a meeting held on March 6, 2001, adopted the following resolution proposing and declaring advisable certain amendments (the "Series C Amendment") to the Certificate of Designation, Rights and Preferences of Series C Convertible Preferred Stock of Integra as filed with the Office of the Secretary of State of the State of Delaware on March 21, 2000:
RESOLVED, that this Board of Directors proposes and hereby deems advisable that the Certificate of Designation, Rights and Preferences of Series C Convertible Preferred Stock of Integra LifeSciences Holdings Corporation (the "Series C Certificate"), be amended as follows:
(1) Amend paragraph 7(a) thereof by replacing the phrase "Series B Preferred Stock" that appears therein with the phrase "Series C Convertible Preferred Stock";
(2) Amend paragraph 7(b) thereof by replacing the phrase "Series B Preferred Stock" that appears therein with the phrase "Series C Convertible Preferred Stock".
SECOND: That the stockholders of the Corporation, at an annual meeting of stockholders called and held upon notice properly given in accordance with Section 222 of the Delaware General Corporation Law, have adopted and approved the Series C Amendment in accordance with the provisions of Section 212 of the Delaware General Corporation Law.
IN WITNESS WHEREOF, said Integra LifeSciences Holdings Corporation has caused this Certificate of Amendment of Certificates of Designation, Rights and Preferences of Series C Preferred Stock to be executed by a duly authorized officer of the Corporation this 15th day of May, 2001.
INTEGRA LIFESCIENCES HOLDINGS CORPORATION | ||
By: | Stuart M. Essig
|
|
Stuart M. Essig, President |